A Multi-center Registry in Taiwan for Patients Suspected of Cardiac Amyloidosis Using 99mTc-pyrophosphate Scans to Improve Diagnosis and Prediction

What this Trial Is About

Cardiac amyloidosis CA involves amyloid deposits in the heart, mainly caused by immunoglobulin light chain amyloidosis AL and transthyretin amyloidosis ATTR. This study focuses on patients in Taiwan, where the common ATTR mutation A97S is linked to left ventricular hypertrophy. Early diagnosis and proper treatment are crucial for better outcomes. The trial aims to improve diagnosis and prognosis by analyzing clinical and imaging data, using artificial intelligence to develop predictive models from 99mTc-PYP scans. Participants suspected or diagnosed with CA will undergo Tc-99m PYP cardiac scans to detect amyloid deposits. The study collects retrospective and prospective data from multiple medical centers in Taiwan, including imaging quality assessments and visual grading by nuclear medicine physicians. Genetic testing and blood and urine tests for AL amyloidosis will be performed when indicated. Follow-up for at least one year will monitor outcomes. Participants will provide clinical data and undergo imaging assessments, including PYP scans graded for amyloid uptake. Researchers will analyze these along with genetic and laboratory tests to build diagnostic and prognostic models. The primary outcome is death within one year, with secondary outcomes including cardiovascular death and hospitalization for heart failure. This observational study helps gather real-world evidence to guide clinical decisions and patient care over the study period.

A Multi-center Cardiac PYP Scan Registry in Taiwan